Rani Therapeutics Holdings, Inc. (RANI): R&D Expense
$20.20M
Year ended 2025-12-31
$18.31M
Trailing 12 months to 2026-06-30
-18.0%
3-year compound annual growth
+10.9%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $20.20M | -24.3% | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | $26.68M | -32.7% | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | $39.62M | +8.2% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $36.61M | +38.2% | 2024-03-20, From 2022-01-01 |
| 2021-12-31 | $26.48M | +119.9% | 2023-03-22, From 2021-01-01 |
| 2020-12-31 | $12.04M | n/a | 2022-03-31, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $20.20M | -24.3% |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | $3.78M | -39.1% |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | $1.04M | -84.4% |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $28.79M | -17.5% |
| Lipocine Inc. (LPCN) | 2025-12-31 | $8.58M | +16.8% |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $145.64M | +75.2% |
| Korsana Biosciences, Inc. (KRSA) | 2025-12-31 | $959.0K | +235.3% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $3.65M | -3.1% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $54.97M | +39.6% |
Compare RANI, NRXP, ATXI, NWBO side by side · Screen every company in Pharmaceutical Preparations ↗